Cell and Gene Commercialization

  1. The Evolution Of Cell And Gene Therapy: Pioneering Breakthroughs For A New Era In Medicine 1/30/2025

    This article explores the rapid evolution of cell and gene therapy (CGT), highlighting its expansion beyond hematology and oncology into autoimmune and metabolic diseases, emphasizing the need for safety, patient access, and a collaborative, knowledge-sharing approach to accelerate innovation and ensure broader therapeutic impact via the "Knowledge Research Organization."

  2. Catalysts of Change: How the Cell and Gene Therapy Market Has Evolved 1/28/2025

    Since 2021, the CGT market has continued to grow, but challenges remain, especially with regard to regulatory compliance.

  3. New Regulatory Survey Findings: Biotech Global Market Access Challenges And Learnings 1/15/2025

    To understand biotech companies’ evolving geographic strategies and perceptions, Arriello recently commissioned a transatlantic survey among regulatory, safety, and quality directors at small/medium biotechs, with respondents in Ireland and North America.

  4. 2025 Forecast For Advanced Therapies 1/8/2025

    As we reflect on the lessons from 2024, it’s time to consider what 2025 may hold for the industry. Special attention is given to oligos, mRNA, cell therapies, and AAV.

  5. What Does InspiroGene Bring To The CGT Space And To The Patients It Serves? 12/30/2024

    Joe DePinto, Head of Cell Gene and Advanced Therapies at McKesson, discusses what InspiroGene brings to the cell and gene therapy (CGT) space and the patients it serves.

  6. Bridging The Gap Between CGT Innovation And Reality 12/30/2024

    Learn about the range of services provided by InspiroGene By McKesson and the company’s unique points of difference as a commercial ally to stakeholders in the CGT industry.

  7. What's Next For Cell And Gene Therapies: Addressing Key Challenges 12/30/2024

    Delve into this exploration of the challenges and opportunities facing CGTs, including manufacturing, supply chain logistics, and the need for greater collaboration among stakeholders.

  8. U.S. Oncologists See Promise In CGTs, But Barriers Loom 12/30/2024

    Explore the findings of a survey of 124 U.S. oncologists focused on better understanding the current use of cell and gene therapies (CGTs) and possible barriers to future adoption.

  9. Optimism For Biopharma In 2025 12/27/2024

    In this closing segment from the executive roundtable discussion, our panelists express their confidence in the industry's mission and maintain a positive outlook for the years ahead.

  10. How Biotechs Can Navigate Market Uncertainty In 2025 12/27/2024

    In this segment of the executive roundtable discussion, our panelists weigh in on how to prepare for what may be a challenging financial climate in 2025.